Loading...
•
Sep 30, 2023
Aclaris Therapeutics Q3 2023 Earnings Report
Aclaris Therapeutics reported a net loss, but is progressing with clinical trials and expects key data readouts soon.
Key Takeaways
Aclaris Therapeutics reported a net loss of $29.3 million for Q3 2023, compared to a net loss of $20.0 million for Q3 2022. Total revenue was $9.3 million, down from $19.0 million in the prior year, primarily due to a one-time upfront payment received in 2022. The company is focused on advancing its clinical development programs, with topline data expected for zunsemetinib in rheumatoid arthritis this month and ATI-1777 in atopic dermatitis around year-end 2023.
Aclaris Therapeutics reported a net loss of $29.3 million for the third quarter of 2023.
Total revenue for Q3 2023 was $9.3 million, compared to $19.0 million for Q3 2022.
The company continues to advance its clinical development programs, with key data readouts expected soon.
Aclaris anticipates its cash, cash equivalents, and marketable securities will be sufficient to fund operations through the end of 2025.
Revenue by Segment
Forward Guidance
Aclaris anticipates its cash, cash equivalents and marketable securities as of September 30, 2023 will be sufficient to fund its operations through the end of 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...